China Pharma Holdings Net Income 2012-2026 | CPHI
China Pharma Holdings net income from 2012 to 2026. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
|
China Pharma Holdings Annual Net Income (Millions of US $) |
|
|---|---|
| 2025 | $-3 |
| 2024 | $-5 |
| 2023 | $-3 |
| 2022 | $-4 |
| 2021 | $-3 |
| 2020 | $-3 |
| 2019 | $-21 |
| 2018 | $-11 |
| 2017 | $-19 |
| 2016 | $-9 |
| 2015 | $-15 |
| 2014 | $-40 |
| 2013 | $-20 |
| 2012 | $5 |
| 2011 | $19 |
|
China Pharma Holdings Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2026-03-31 | $-1 |
| 2025-12-31 | $-1 |
| 2025-09-30 | $-1 |
| 2025-06-30 | $-1 |
| 2025-03-31 | $-1 |
| 2024-12-31 | $-1 |
| 2024-09-30 | $-1 |
| 2024-06-30 | $-1 |
| 2024-03-31 | $-1 |
| 2023-12-31 | $-1 |
| 2023-09-30 | $-1 |
| 2023-06-30 | $-1 |
| 2023-03-31 | $0 |
| 2022-12-31 | $-1 |
| 2022-09-30 | $-1 |
| 2022-06-30 | $-1 |
| 2022-03-31 | $-1 |
| 2021-12-31 | $-1 |
| 2021-09-30 | $-1 |
| 2021-06-30 | $-1 |
| 2021-03-31 | $-1 |
| 2020-12-31 | $-1 |
| 2020-09-30 | $-1 |
| 2020-06-30 | $0 |
| 2020-03-31 | $-1 |
| 2019-12-31 | $-19 |
| 2019-09-30 | $-1 |
| 2019-06-30 | $-1 |
| 2019-03-31 | $0 |
| 2018-12-31 | $-8 |
| 2018-09-30 | $-2 |
| 2018-06-30 | $-1 |
| 2018-03-31 | $0 |
| 2017-12-31 | $-14 |
| 2017-09-30 | $-2 |
| 2017-06-30 | $-2 |
| 2017-03-31 | $-1 |
| 2016-12-31 | $-3 |
| 2016-09-30 | $-2 |
| 2016-06-30 | $-2 |
| 2016-03-31 | $-2 |
| 2015-12-31 | $-15 |
| 2015-09-30 | $3 |
| 2015-06-30 | $1 |
| 2015-03-31 | $-4 |
| 2014-12-31 | $-22 |
| 2014-09-30 | $-6 |
| 2014-06-30 | $-9 |
| 2014-03-31 | $-2 |
| 2013-12-31 | $-10 |
| 2013-09-30 | $-2 |
| 2013-06-30 | $-4 |
| 2013-03-31 | $-3 |
| 2012-12-31 | $-1 |
| 2012-09-30 | $1 |
| 2012-06-30 | $2 |
| 2012-03-31 | $3 |
| 2011-12-31 | $4 |
| 2011-09-30 | $5 |
| 2011-06-30 | $5 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.026B | $0.004B |
| CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |